MRCC treated with first-line sunitinib or pazopanib: is toxicity prognostic?

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • Among patients with metastatic renal cell carcinoma (mRCC) receiving first-line sunitinib or pazopanib, those who required dose reduction due to adverse events (AEs) demonstrated improved PFS and OS.

Why this matters

  • Sunitinib- and pazopanib-related AEs lead to dose interruptions or...